The Effect on Envelope of Motion in Asymptomatic Bruxers
Launched by REGION VÄSTERBOTTEN · Nov 1, 2022
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a treatment called botulinum neurotoxin might help people who grind their teeth (a condition known as bruxism) and have experienced some wear on their teeth. The researchers want to see if this treatment can change the way the jaw and neck move, which could be beneficial for those with tooth wear. The trial is currently recruiting participants, and anyone aged 9 years or older may be eligible, as long as they have some tooth wear into the dentin (the layer under the outer enamel of the teeth).
To participate, you should not have any issues with your jaw joint (temporomandibular pathology), be taking medications that affect the brain, or have any conditions that impact your muscles or nervous system. If you join the trial, you can expect to receive the botulinum neurotoxin treatment and be monitored for its effects. This study is important because it could lead to new ways to help people suffering from bruxism and tooth wear, improving their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Tooth wear into dentin.
- Exclusion Criteria:
- • No temporomandibular pathology.
- • No drugs affecting the central nervous system.
- • No conditions affecting muscles or central nervous system.
About Region Västerbotten
Region Västerbotten is a leading healthcare authority in northern Sweden, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a sponsor, Region Västerbotten focuses on collaborating with academic institutions, industry partners, and healthcare professionals to facilitate groundbreaking studies that address critical health challenges. With a commitment to ethical standards and patient safety, the organization aims to contribute to the global body of medical knowledge while enhancing the quality of healthcare services in the region. Through its robust infrastructure and expertise, Region Västerbotten strives to drive scientific discovery and foster an environment of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Umeå, , Sweden
Umeå, Västerbotten, Sweden
Patients applied
Trial Officials
Mattias Pettersson, PhD
Principal Investigator
Umeå University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials